Literature DB >> 11498523

Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study.

Y Mateo1, B Fernández-Pastor, J J Meana.   

Abstract

1. The effects of desipramine (3 mg kg(-1) i.p.) and clorgyline (1 mg kg(-1) i.p.) on extracellular noradrenaline (NA) in the locus coeruleus (LC) and cingulate cortex were assessed in freely-moving rats by dual-probe microdialysis. Functional activities of alpha(2)-adrenoceptors regulating NA release in the LC and cingulate cortex were determined by systemic (0.3 mg kg(-1) i.p.) or local (0.1 - 100 microM) clonidine administration. 2. Extracellular NA was increased in the LC and cingulate cortex following acute desipramine but not clorgyline treatment. Systemic clonidine decreased NA similarly in desipramine-, clorgyline-, and saline-treated animals, in both brain areas. 3. Long-term (twice daily, 14 days) but not short-term (twice daily, 7 days) desipramine, and long-term clorgyline (once daily, 21 days) treatments increased NA (3 fold) in cingulate cortex but not in the LC. Following long-term treatments, responses of NA to systemic clonidine were attenuated in the LC and cingulate cortex. 4. Clonidine perfusion by reverse dialysis into the cingulate cortex decreased local NA (-55 +/- 9%). The effect was attenuated by long-term desipramine (-31 +/- 9%) and clorgyline (-10 +/- 2%) treatments. 5. Clonidine perfusion by reverse dialysis into the LC decreased NA in the LC (-89 +/- 2%) and in cingulate cortex (-52 +/- 12%). This effect was attenuated in the LC following long-term desipramine (-72 +/- 4%) and clorgyline (-62 +/- 12%) treatments but it was not modified in the cingulate cortex (-57 +/- 10% and -68 +/- 6%, respectively). 6. These findings demonstrate that chronic desipramine or clorgyline treatments increase NA in noradrenergic terminal areas and desensitize alpha(2)-adrenoceptors modulating local NA release at somatodendritic and terminal levels. However, somatodendritic alpha(2)-adrenoceptors that control LC firing activity are not desensitized.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498523      PMCID: PMC1621148          DOI: 10.1038/sj.bjp.0704196

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  62 in total

1.  Modulation by antidepressant drugs of CNS postsynaptic alpha 2-adrenoceptors mediating mydriasis in the rat.

Authors:  A Menargues; R Obach; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

2.  Increased alpha 2-adrenoceptor density in the frontal cortex of depressed suicide victims.

Authors:  J J Meana; J A García-Sevilla
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

3.  Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors.

Authors:  P Blier; C de Montigny
Journal:  Neuroscience       Date:  1985-12       Impact factor: 3.590

4.  Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat.

Authors:  T Dennis; R L'Heureux; C Carter; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

5.  The release of catecholamines in hypothalamus and locus coeruleus is modulated by peripheral chemoreceptors.

Authors:  S T Kaehler; N Singewald; A Philippu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-10       Impact factor: 3.000

6.  Acute and long-term regulation of brain alpha 2-adrenoceptors after manipulation of noradrenergic transmission in the rat.

Authors:  M T Giralt; J A García-Sevilla
Journal:  Eur J Pharmacol       Date:  1989-05-30       Impact factor: 4.432

7.  The effects of acute and chronic desipramine on the thermogenic and hypoactivity responses to alpha 2-agonists in reserpinized and normal mice.

Authors:  D J Bill; I E Hughes; R J Stephens
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

8.  Antidepressant actions on brain noradrenergic neurons.

Authors:  R J Valentino; A L Curtis; D G Parris; R G Wehby
Journal:  J Pharmacol Exp Ther       Date:  1990-05       Impact factor: 4.030

Review 9.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

10.  Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: effects of drugs affecting noradrenergic transmission.

Authors:  R L'Heureux; T Dennis; O Curet; B Scatton
Journal:  J Neurochem       Date:  1986-06       Impact factor: 5.372

View more
  18 in total

1.  Desipramine selectively potentiates norepinephrine-elicited ERK1/2 activation through the α2A adrenergic receptor.

Authors:  Christopher Cottingham; Adrian Jones; Qin Wang
Journal:  Biochem Biophys Res Commun       Date:  2012-03-03       Impact factor: 3.575

2.  Neuroanatomical targets of reboxetine and bupropion as revealed by pharmacological magnetic resonance imaging.

Authors:  Sakthivel Sekar; J Van Audekerke; G Vanhoutte; A S Lowe; A M Blamire; A Van der Linden; T Steckler; M Shoaib; Marleen Verhoye
Journal:  Psychopharmacology (Berl)       Date:  2011-05-07       Impact factor: 4.530

3.  The function of alpha-2-adrenoceptors in the rat locus coeruleus is preserved in the chronic constriction injury model of neuropathic pain.

Authors:  Cristina Alba-Delgado; Gisela Borges; Pilar Sánchez-Blázquez; Jorge E Ortega; Igor Horrillo; Juan A Mico; J Javier Meana; Fani Neto; Esther Berrocoso
Journal:  Psychopharmacology (Berl)       Date:  2011-10-29       Impact factor: 4.530

4.  The N251K functional polymorphism in the alpha(2A)-adrenoceptor gene is not associated with depression: a study in suicide completers.

Authors:  Idoia Martín-Guerrero; Luis F Callado; Koldo Saitua; Guadalupe Rivero; Africa García-Orad; J Javier Meana
Journal:  Psychopharmacology (Berl)       Date:  2005-12-07       Impact factor: 4.530

5.  The antidepressant desipramine is an arrestin-biased ligand at the α(2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo.

Authors:  Christopher Cottingham; Yunjia Chen; Kai Jiao; Qin Wang
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

6.  Effect of subchronic corticosterone administration on α2-adrenoceptor functionality in rat brain: an in vivo and in vitro study.

Authors:  Igor Horrillo; Jorge E Ortega; Rebeca Diez-Alarcia; Leyre Urigüen; J Javier Meana
Journal:  Psychopharmacology (Berl)       Date:  2016-09-04       Impact factor: 4.530

7.  Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior.

Authors:  Han-Ting Zhang; Lisa R Whisler; Ying Huang; Yang Xiang; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

Review 8.  α2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy.

Authors:  Christopher Cottingham; Qin Wang
Journal:  Neurosci Biobehav Rev       Date:  2012-08-13       Impact factor: 8.989

9.  Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3).

Authors:  John J Mooney; Jacqueline A Samson; John Hennen; Kathleen Pappalardo; Nancy McHale; Jonathan Alpert; Martha Koutsos; Joseph J Schildkraut
Journal:  J Psychiatr Res       Date:  2007-08-28       Impact factor: 4.791

10.  Heterotrimeric g proteins: insights into the neurobiology of mood disorders.

Authors:  Javier González-Maeso; J Javier Meana
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.